The key targets of protective antibodies against Plasmodium falciparum remain largely
unknown. In this study, we determined immunoreactivity to 1827 recombinant proteins …

Plasmodium falciparum malaria is a disease causing high morbidity and mortality rates
worldwide, mainly in sub-Saharan Africa. Candidates have been identified for vaccines …

Induction of humoural immunity is critical for clinical protection against malaria. More than
100 malaria vaccine candidates have been investigated at different developmental stages …

The malaria vaccine candidate antigen, SE36, is based on the N-terminal 47 kDa domain of
Plasmodium falciparum serine repeat antigen 5 (SERA5). In epidemiological studies, we …

Malaria is a life-threatening disease and one of the main causes of morbidity and mortality in
the human population. The disease also results in a major socio-economic burden. The …

Much of the gain in malaria control, in terms of regional achievements in restricting
geographical spread and reducing malaria cases and deaths, can be attributed to large …

Background The GMZ2/alum candidate malaria vaccine had an efficacy of 14%(95%
confidence interval [CI]: 3.6%, 23%) against clinical malaria over 6 months of follow-up in a …

Clinical immunity to malaria develops after repeated exposure to Plasmodium falciparum
parasites. Broadly reactive antibodies against parasite antigens expressed on the surface of …

Malaria causes about 216 million clinical cases and 0.7 million deaths annually. One
promising route to address malaria is vaccination. However, so far, not even a single …

Considerable progress has been made in malaria control in the last two decades, but
progress has stalled in the last few years. New tools are needed to achieve public health …